CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.

Happy Thanksgiving from all of us at CNS Pharmaceuticals! We hope you enjoy a day of good company and good food.

Florida Girl, 8, Girl, Spends Holiday In DC For Rare Brain Cancer Treatment  https://ibn.fm/7js7F

Industry News:    Brain Cancer Thrives By Hijacking Mechanisms To Boost Synapse Strength  https://ibn.fm/dTSps     #braincancer  #glioblastoma #neuro-oncology

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

https://bit.ly/3MW5gmv 
#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Finger-prick Test Could Help Spot Brain Cancer Recurrence Sooner  https://ibn.fm/H3BYY    #braincancer  #glioblastoma #neuro-oncology

Meet our dedicated, experienced team here: https://bit.ly/3tCAjx9 

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:    Actor Had Brain Tumor The Size Of A Lime  https://ibn.fm/gEjkC    #braincancer  #glioblastoma #neuro-oncology

Watch this video on how our lead product candidate, Berubicin is designed to work: https://bit.ly/3ZWWubF  

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

https://bit.ly/46fHoB9 
 #GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Lung Cancer Cells Covertly Thrive In Brain Under Guise Of Protection, Stanford Medicine Study Finds  https://ibn.fm/zAqz9   #braincancer  #glioblastoma #neuro-oncology

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-7.39M -	-3.88M 47.55%	-9.46M 143.93%	-14.04M 48.41%	-15.27M 8.82%	-18.85M 23.42%
depreciation and amortization		1.96K -	11.10K 467.57%	13.07K 17.79%	11.76K 10.05%	4.13K 64.83%
deferred income tax				-714.87K -
stock based compensation	110.24K -	477.10K 332.78%	1.29M 171.10%	1.72M 33.28%	1.20M 30.22%	1.01M 16.26%
change in working capital	83.78K -	-425.62K 608.04%	833.78K 295.90%	-1.24M 248.56%	3.16M 355.47%	1.32M 58.23%
accounts receivables
inventory
accounts payables	71.37K -	153.61K 115.24%	656.83K 327.60%	576.49K 12.23%	1.70M 194.97%	1.32M 22.26%
other working capital	12.41K -	-579.23K 4,767.81%	176.95K 130.55%	-1.82M 1,125.78%	1.46M 180.65%	-1.32M 190.30%
other non cash items	6.48M -	270.31K 95.83%	1.58K 99.41%	714.87K 45,059.00%	337.25K 52.82%	3.70M 997.01%
net cash provided by operating activities	-716.38K -	-3.55M 396.03%	-7.32M 105.94%	-13.54M 85.00%	-10.56M 22.02%	-14.14M 33.93%
investments in property plant and equipment		-20.12K -	-17.95K 10.81%	-5.75K 67.97%	-4.42K 23.07%	-3.90K 11.78%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites		-20.12K -	-17.95K 10.81%	-5.75K 67.97%	-4.42K 23.07%	-3.90K 11.78%
debt repayment		-35K -	-43.08K 23.09%	-477.49K 1,008.35%	-427.70K 10.43%
common stock issued	390.50K -	10.29M 2,536.30%	14.22M 38.15%	4.65M 67.28%	16.04M 244.62%	2.32M 85.55%
common stock repurchased
dividends paid
other financing activites	770.48K -	10.26K 98.67%	-45K 538.64%	332.75K 839.44%	2.73K 99.18%	2.32M 84,744.44%
net cash used provided by financing activities	1.16M -	10.26M 783.72%	14.13M 37.76%	4.51M 68.10%	15.61M 246.26%	4.64M 70.30%
effect of forex changes on cash
net change in cash	444.59K -	6.69M 1,403.89%	6.80M 1.68%	-9.03M 232.90%	5.05M 155.90%	-9.51M 288.22%
cash at beginning of period	110.54K -	555.13K 402.19%	7.24M 1,204.42%	14.04M 93.88%	5.00M 64.35%	10.06M 100.93%
cash at end of period	555.13K -	7.24M 1,204.42%	14.04M 93.88%	5.00M 64.35%	10.06M 100.93%	548.72K 94.54%
operating cash flow	-716.38K -	-3.55M 396.03%	-7.32M 105.94%	-13.54M 85.00%	-10.56M 22.02%	-14.14M 33.93%
capital expenditure		-20.12K -	-17.95K 10.81%	-5.75K 67.97%	-4.42K 23.07%	-3.90K 11.78%
free cash flow	-716.38K -	-3.57M 398.84%	-7.34M 105.28%	-13.54M 84.63%	-10.56M 22.02%	-14.14M 33.91%

COM:CNSPHARMA

CNS Pharmaceuticals, Inc.

Last Close

0.13

22/11 21:00

Market Cap

1.52M

Beta: -

Volume Today

194.47K

Avg: -

Preview